COVID-19 may cause changes in the brain stem and frontal lobe that could lead to fatigue, impacts in motor signal processing, insomnia, and depression, according to emerging research recently presented at the Radiological Society of North America (RSNA) annual conference in Chicago.
New research, based on susceptibility-weighted magnetic resonance imaging (MRI) of the brain, reveals significant differences in the brain stem and frontal lobe up to six months after people had COVID-19.
For the study, researchers obtained susceptibility-weighted MRI scans from 46 people within six months of recovery from COVID-19 and compared them to 30 healthy controls. The researchers identified high susceptibility values with significant clusters in the frontal lobe and brain stem for those who had COVID-19.
The frontal lobe clusters included portions of the right and left orbito-inferior frontal gyrus and adjacent areas of white matter, according to the researchers, who presented their findings at the recent Radiological Society of North America (RSNA) annual conference in Chicago.
“These brain regions are linked with fatigue, insomnia, anxiety, depression, headaches and cognitive problems,” noted study co-author Sapna S. Mishra, Ph.D(c), who is affiliated with the Indian Institute of Technology in Delhi.
Mishra said the “significant abnormalities in COVID survivors” also included a cluster in the right ventral diencephalon region of the brain stem. The researchers noted this region is associated with a variety of functions including sensory and motor signal processing, hormone release, and regulation of circadian rhythms.
In order to determine potential long-term implications of these brain changes, the researchers are currently in the midst of conducting a longitudinal study of the same patient cohort.
“(The current) study points to serious long-term complications that may be caused by the coronavirus, even months after recovery from the infection,” noted Mishra. “The present findings are from the small temporal window. However, the longitudinal time points across a couple of years will elucidate if there exists any permanent change.”
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.